Detalhe da pesquisa
1.
Ensitrelvir in patients with SARS-CoV-2: A retrospective chart review.
J Infect Chemother
; 2024 Feb 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38367932
2.
Efficacy and Safety of Ensitrelvir in Patients With Mild-to-Moderate Coronavirus Disease 2019: The Phase 2b Part of a Randomized, Placebo-Controlled, Phase 2/3 Study.
Clin Infect Dis
; 76(8): 1403-1411, 2023 04 17.
Artigo
em Inglês
| MEDLINE | ID: mdl-36477182
3.
Efficacy and safety of zuranolone in Japanese adults with major depressive disorder: A double-blind, randomized, placebo-controlled, phase 2 clinical trial.
Psychiatry Clin Neurosci
; 77(9): 497-509, 2023 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-37252829
4.
Safety, Tolerability, and Pharmacokinetics of the Novel Antiviral Agent Ensitrelvir Fumaric Acid, a SARS-CoV-2 3CL Protease Inhibitor, in Healthy Adults.
Antimicrob Agents Chemother
; 66(10): e0063222, 2022 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36094202
5.
A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part.
Antimicrob Agents Chemother
; 66(10): e0069722, 2022 10 18.
Artigo
em Inglês
| MEDLINE | ID: mdl-36098519
6.
Open-label study of the safety, pharmacokinetics, and effectiveness of a 2 mg/kg dose of baloxavir marboxil 2% granules in children <20 kg with influenza.
J Infect Chemother
; 27(8): 1223-1229, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-34045119
7.
A phase 3 randomized controlled trial of a COVID-19 recombinant vaccine S-268019-b versus ChAdOx1 nCoV-19 in Japanese adults.
Sci Rep
; 14(1): 9830, 2024 04 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-38684712
8.
A SARS-CoV-2 recombinant spike protein vaccine (S-268019-b) for COVID-19 prevention during the Omicron-dominant period: A phase 3, randomised, placebo-controlled clinical trial.
Vaccine
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38734495
9.
Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial.
JAMA Netw Open
; 7(2): e2354991, 2024 Feb 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-38335000
10.
A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations.
Clin Drug Investig
; 43(10): 785-797, 2023 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-37798608
11.
Evaluation of Drug-Drug Interactions of Ensitrelvir, a SARS-CoV-2 3CL Protease Inhibitor, With Transporter Substrates Based on In Vitro and Clinical Studies.
J Clin Pharmacol
; 63(8): 918-927, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37043676
12.
Evaluation of the Drug-Drug Interaction Potential of Ensitrelvir Fumaric Acid with Cytochrome P450 3A Substrates in Healthy Japanese Adults.
Clin Drug Investig
; 43(5): 335-346, 2023 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-37171749
13.
Safety and immunogenicity of a booster dose of S-268019-b: Interim findings of a Phase 3, open-label clinical study in Japan.
Vaccine X
; 15: 100390, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37822891
14.
A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part).
Medicine (Baltimore)
; 102(8): e33024, 2023 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-36827007
15.
Pharmacokinetics, safety, and tolerability of single and multiple doses of zuranolone in Japanese and White healthy subjects: A phase 1 clinical trial.
Neuropsychopharmacol Rep
; 43(3): 346-358, 2023 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37366077
16.
Results from a preclinical study in rodents and a Phase 1/2, randomized, double-blind, placebo-controlled, parallel-group study of COVID-19 vaccine S-268019-a in Japanese adults.
Vaccine
; 41(11): 1834-1847, 2023 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-36572603
17.
Relationship between baseline clinical characteristics and efficacy of lusutrombopag in thrombocytopenic patients with chronic liver disease: post hoc analysis of two placebo-controlled phase 3 trials.
Curr Med Res Opin
; 38(2): 303-310, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34904508
18.
Phase 1/2 clinical trial of COVID-19 vaccine in Japanese participants: A report of interim findings.
Vaccine
; 40(27): 3721-3726, 2022 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-35606235
19.
Homologous and heterologous booster vaccinations of S-268019-b, a recombinant S protein-based vaccine with a squalene-based adjuvant, enhance neutralization breadth against SARS-CoV-2 Omicron subvariants in cynomolgus macaques.
Vaccine
; 40(52): 7520-7525, 2022 12 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36372670
20.
Immunogenicity and safety of booster dose of S-268019-b or BNT162b2 in Japanese participants: An interim report of phase 2/3, randomized, observer-blinded, noninferiority study.
Vaccine
; 40(32): 4328-4333, 2022 07 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-35738968